Centocor's R&D spin-off Tocor
On July 1, Centocor will exercise option to purchase all 2,875,000 outstanding shares of callable common stock of Tocor. Centocor spun off Tocor in 1989 to carry on research in monoclonal antibody-based therapies for inflammatory diseases ("The Pink Sheet," Jan 15, 1990, p. 14). Repurchase will be made through issuance of 2 mil. shares of Centocor stock; 1991 2nd quarter results will register a $ 71 mil. charge to earnings for acquired R&D. The deal means Centocor re-acquires rights to mAB products being developed for rheumatoid arthritis, multiple sclerosis and lupus erythematosus.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth